Xanthine Oxidase Inhibition In SARS-Cov-2 Infection

Abstract

Background: The literature on xanthine oxidase inhibition and its implications in SARS-CoV-2 infection presents a multifaceted view of the role of oxidative stress in COVID-19 pathogenesis and treatment. Literature Review: The main body of the review discusses various mechanisms by which SARS-CoV-2 induces oxidative stress and the subsequent inflammatory responses that exacerbate the disease. The role of reactive oxygen species (ROS) is highlighted, with studies indicating that they not only contribute to viral replication but also to the systemic inflammatory response, including the cytokine storm observed in severe cases (DE FLORA et al., 2021). Additionally, the potential of antioxidants to restore oxidative balance disrupted by the virus is explored, with specific agents such as vitamins C, D, and various plant-derived compounds being noted for their therapeutic potential. A systematic review of antioxidant therapy in COVID-19 reinforces the notion that while there are indications of benefits, the variability in study quality and outcomes necessitates further research (Sharma et al., 2024). The collective findings suggest that while antioxidant therapies, including xanthine oxidase inhibition, hold promise, the complexity of COVID-19 and individual patient factors must be considered in future clinical trials to optimize treatment strategies. Conclusion: In conclusion, the literature indicates a significant interplay between oxidative stress and SARS-CoV-2 infection, with xanthine oxidase inhibition and antioxidant therapies emerging as potentially valuable therapeutic avenues. However, the need for more rigorous clinical trials to validate these findings is paramount, given the complexities involved in treating COVID-19.